Clinical trial
Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission: a Prospective, Pilot Study.
NCT03244709 is registered in ClinicalTrials.gov with Hospital of Prato as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission: a Prospective, Pilot Study.
- Lead sponsor
- Hospital of Prato
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- January 1, 2015
- Completion date
- December 31, 2017
- Enrollment
- 15 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.